Hironte Injection (Sodium Hyaluronate) (Pre-filled)

Adult dosage

Administer 25 mg of sodium hyaluronate once weekly for 5 consecutive weeks, either intra-articularly into the knee joint or shoulder joint (shoulder joint cavity, subacromial bursa, or bicipital tendon sheath). The frequency of administration may be adjusted appropriately based on symptoms. Administration should be performed under strict aseptic technique as this medicine is delivered into the knee joint.

This medicine should not be used in certain patients. For example, individuals who are allergic to this medicine or its components should not receive this treatment. Additionally, this medicine should not be used if there are skin diseases or infections at the joint site. Patients with liver function issues or those with a history of liver disorders should also exercise caution when receiving this medicine. People with allergies to avian proteins should avoid this medicine. When using this medicine, careful monitoring is required. Rarely, severe allergic reactions or shock may occur, so if any unusual symptoms appear, administration should be stopped immediately, and appropriate treatment should be received. Symptoms such as swelling around the face or eyes, rash, and itching may occur; in such cases, treatment should also be stopped. Temporary pain, swelling, redness, heat feeling, and occasionally bleeding or severe pressure sensations may appear at the injection site. Symptoms such as nausea, vomiting, fever, and headache have also been reported. If arthritis is severe or inflammation is pronounced, it is advisable to alleviate inflammation before using this medicine. After administration, care should be taken to stabilize the injection site and prevent the drug from leaking outside the joint. Patients with rheumatoid arthritis or gout arthritis may experience temporarily worsened inflammation, necessitating caution. Intense exercise or prolonged weight-bearing activities should be avoided within 48 hours after administration. The safety or efficacy of administering this medicine concurrently with other intra-articular injectables has not been established; therefore, co-administration should be avoided. Women who are pregnant or may become pregnant should use this medicine cautiously, as its safety has not been fully confirmed, and it should only be used if the benefits outweigh the risks. This medicine may also be transmitted through breast milk, so breastfeeding should be avoided during treatment. When administering this medicine to children, it should be used cautiously only when absolutely necessary, as its safety has not been sufficiently established. Older patients may have decreased bodily functions, thus requiring more careful administration. This medicine should be administered under strict aseptic conditions, and if symptoms do not improve, administration should be limited to a maximum of 5 times. If there is excess fluid accumulated in the joint, it is advisable to drain the fluid before administration. Intravenous administration is prohibited, and it is not suitable for use in the eye. During injection, an appropriate syringe needle should be used, and it is safe to slowly draw the solution into the syringe as some may cling to the ampoule. When cutting the ampoule, it should be thoroughly cleaned to prevent contaminants, and care should be taken as precipitation may occur when mixed with certain disinfectants. This medicine is for single use, so any remaining unused portion must be disposed of immediately after opening. Administering a local anesthetic before injection may help reduce pain.

Serious side effects

• Urticaria
• edema (facial, eyelid, etc.)
• shock

Mild side effects

• Facial flushing
• itching
• pain
• swelling
• edema
• redness
• heat sensation
• local severe pressure
• petechiae
• nausea

This medicine should be stored in a sealed container to prevent exposure to air, maintaining a storage temperature between 1 and 30 degrees Celsius to preserve its efficacy and safety.

Appearance

A colorless and transparent viscous solution filled in a glass tube capped with rubber stoppers at both ends (part of the pre-filled syringe system).

Package unit

2.5 milliliters × 10, 50, 100 vials